Sign In
Buy RGEN
$149.78
+2.72 (+1.85%)
At Close: Aug 04, 2026
Repligen Opens Training & Innovation Center to Elevate Customer Experience
07:30am, Tuesday, 24'th Sep 2024
WALTHAM, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its
Repligen Corporation to Present at Wells Fargo Healthcare Conference
07:30am, Friday, 23'rd Aug 2024
WALTHAM, Mass., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting
Exclusive: Repligen in bid for reagent vendor Maravai, sources say
11:46am, Friday, 16'th Aug 2024
Repligen , a provider of drug manufacturing equipment, has approached Maravai LifeSciences Holdings , a vaccine capping reagent vendor that has a market value of $2.2 billion, with an acquisition offe
Here's Why Shares in This Hot Healthcare Stock Surged This Week
07:09am, Friday, 02'nd Aug 2024
A far larger peer backs up Repligen's market commentary. Bioprocessing customers are working through inventory, and orders growth is bouncing back.
These Analysts Revise Their Forecasts On Repligen Following Q2 Results
02:50pm, Wednesday, 31'st Jul 2024
Repligen Corporation RGEN reported in-line earnings for its second quarter on Tuesday.
Repligen's (RGEN) Q2 Earnings & Revenues Meet Estimates
11:51am, Wednesday, 31'st Jul 2024
Repligen's (RGEN) second-quarter earnings and revenues match estimates. The company narrows its revenue guidance for 2024.
Repligen Corporation (RGEN) Q2 2024 Earnings Call Transcript
03:03pm, Tuesday, 30'th Jul 2024
Repligen Corporation [RGEN] Q2 2024 Earnings Conference Call July 30, 2024 8:30 AM ET Company Participants Tony Hunt - CEO Jason Garland - CFO Olivier Loeillot - President & CCO Sondra Newman - IR Con
Repligen Lowers Guidance On China Weakness, Analyst Expects
12:01pm, Tuesday, 30'th Jul 2024
Tuesday, Repligen Corporation RGEN reported second-quarter sales of $154.1 million, almost in line with the consensus estimate of $154.12 million.
Repligen (RGEN) Q2 Earnings Meet Estimates
09:46am, Tuesday, 30'th Jul 2024
Repligen (RGEN) came out with quarterly earnings of $0.33 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.53 per share a year ago.
Repligen Reports Second Quarter 2024 Financial Results
07:30am, Tuesday, 30'th Jul 2024
WALTHAM, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its s
Repligen Announces Agreement to Acquire Chromatography Innovator Tantti
04:00pm, Monday, 29'th Jul 2024
WALTHAM, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a
Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for
11:06am, Tuesday, 23'rd Jul 2024
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen to Report Second Quarter 2024 Financial Results
07:30am, Tuesday, 16'th Jul 2024
Webcast and Conference Call to Be Held Tuesday, July 30, 2024, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, July 30, 2024, at 8:30 a.m. ET
Repligen (RGEN) Soars 4.4%: Is Further Upside Left in the Stock?
08:35am, Monday, 24'th Jun 2024
Repligen (RGEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Top 3 Health Care Stocks That Could Blast Off In June
08:22am, Friday, 21'st Jun 2024
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
